StreetInsider.com News Articles

Form S-8 Passage BIO, Inc.

Wed, 04 Mar 2026 16:06:00 -0500

si-local-file:///var/storage/secattach/20260304/26110984.html

Form S-8 Passage BIO, Inc.

Wed, 04 Mar 2026 16:06:00 -0500

si-local-file:///var/storage/secattach/20260304/26110984.html

Passage Bio Inc. (PASG) PT Lowered to $23 at Canaccord

Wed, 04 Mar 2026 07:00:08 -0500

Canaccord analyst Whitney Ijem lowered the price target on Passage Bio Inc. (NASDAQ: PASG) to $23.00 (from $67.00) while maintaining a Buy rating.

Form 10-K Passage BIO, Inc. For: Dec 31

Tue, 03 Mar 2026 07:16:00 -0500

si-local-file:///var/storage/secattach/20260303/26096421.html

Form 10-K Passage BIO, Inc. For: Dec 31

Tue, 03 Mar 2026 07:16:00 -0500

si-local-file:///var/storage/secattach/20260303/26096421.html

Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights

Tue, 03 Mar 2026 07:00:00 -0500

Enrolled first three FTD-GRN patients in Cohort 3 of ongoing upliFT-D study

Treated first FTD-C9orf72 patient with Dose 2 PBFT02 in Cohort 4 of upliFT-D study

On track to report updated interim safety and biomarker data from upliFT-D and obtain regulatory feedback on FTD-GRN registrational trial design in 1H 2026

Advancing differentiated preclinical program for Huntington’s with clinical candidate selection expected in 2H 2026

Cash runway through 1Q 2027

PHILADELPHIA, March 03, 2026 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused

Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights

Tue, 03 Mar 2026 07:00:00 -0500

Enrolled first three FTD-GRN patients in Cohort 3 of ongoing upliFT-D study

Treated first FTD-C9orf72 patient with Dose 2 PBFT02 in Cohort 4 of upliFT-D study

On track to report updated interim safety and biomarker data from upliFT-D and obtain regulatory feedback on FTD-GRN registrational trial design in 1H 2026

Advancing differentiated preclinical program for Huntington’s with clinical candidate selection expected in 2H 2026

Cash runway through 1Q 2027

PHILADELPHIA, March 03, 2026 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused

Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights

Tue, 03 Mar 2026 07:00:00 -0500

Enrolled first three FTD-GRN patients in Cohort 3 of ongoing upliFT-D study

Treated first FTD-C9orf72 patient with Dose 2 PBFT02 in Cohort 4 of upliFT-D study

On track to report updated interim safety and biomarker data from upliFT-D and obtain regulatory feedback on FTD-GRN registrational trial design in 1H 2026

Advancing differentiated preclinical program for Huntington’s with clinical candidate selection expected in 2H 2026

Cash runway through 1Q 2027

PHILADELPHIA, March 03, 2026 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused

Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights

Tue, 03 Mar 2026 07:00:00 -0500

Enrolled first three FTD-GRN patients in Cohort 3 of ongoing upliFT-D study

Treated first FTD-C9orf72 patient with Dose 2 PBFT02 in Cohort 4 of upliFT-D study

On track to report updated interim safety and biomarker data from upliFT-D and obtain regulatory feedback on FTD-GRN registrational trial design in 1H 2026

Advancing differentiated preclinical program for Huntington’s with clinical candidate selection expected in 2H 2026

Cash runway through 1Q 2027

PHILADELPHIA, March 03, 2026 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused

Form 8-K Passage BIO, Inc. For: Mar 03

Tue, 03 Mar 2026 07:00:00 -0500

si-local-file:///var/storage/secattach/20260303/26096318.html

Form 8-K Passage BIO, Inc. For: Mar 03

Tue, 03 Mar 2026 07:00:00 -0500

si-local-file:///var/storage/secattach/20260303/26096318.html

Passage Bio to Participate in Upcoming Investor Conferences

Thu, 19 Feb 2026 07:00:00 -0500

PHILADELPHIA, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced management will participate in the following upcoming investor conferences:

Oppenheimer 36^th Annual Healthcare Life Sciences Conference
Format: Management will participate in a presentation and investor meetings
Date: Thursday, February 26, 2026
Presentation Time: 8:40 a.m. ET
Location: Virtual

TD Cowen 46^th Annual Health Care Conference
Format: Management will participate in a presentation and investor meetings
Date: Wednesday, March 4, 2026
Presentation Time: 1:50 p.m. ET
Location:

Passage Bio to Participate in Upcoming Investor Conferences

Thu, 19 Feb 2026 07:00:00 -0500

TD Cowen 46^th Annual Health Care Conference
Format: Management will participate in a presentation and investor meetings
Date: Wednesday, March 4, 2026
Presentation Time: 1:50 p.m. ET
Location:

Passage Bio to Participate in Upcoming Investor Conferences

Thu, 19 Feb 2026 07:00:00 -0500

TD Cowen 46^th Annual Health Care Conference
Format: Management will participate in a presentation and investor meetings
Date: Wednesday, March 4, 2026
Presentation Time: 1:50 p.m. ET
Location:

Passage Bio to Participate in Upcoming Investor Conferences

Thu, 19 Feb 2026 07:00:00 -0500

TD Cowen 46^th Annual Health Care Conference
Format: Management will participate in a presentation and investor meetings
Date: Wednesday, March 4, 2026
Presentation Time: 1:50 p.m. ET
Location:

Form 4 Passage BIO, Inc. For: Jan 08 Filed by: Chou William

Mon, 12 Jan 2026 16:04:00 -0500

si-local-file:///var/storage/secattach/20260112/25837798.html

Form 4 Passage BIO, Inc. For: Jan 08 Filed by: Chou William

Mon, 12 Jan 2026 16:04:00 -0500

si-local-file:///var/storage/secattach/20260112/25837798.html

Form 4 Passage BIO, Inc. For: Jan 08 Filed by: Borthwick Kathleen

Mon, 12 Jan 2026 16:03:00 -0500

si-local-file:///var/storage/secattach/20260112/25837784.html

Form 4 Passage BIO, Inc. For: Jan 08 Filed by: Borthwick Kathleen

Mon, 12 Jan 2026 16:03:00 -0500

si-local-file:///var/storage/secattach/20260112/25837784.html

Form 4 Passage BIO, Inc. For: Jan 08 Filed by: Borthwick Kathleen

Mon, 12 Jan 2026 16:03:00 -0500

si-local-file:///var/storage/secattach/20260112/25837785.html

Form 4 Passage BIO, Inc. For: Jan 08 Filed by: Borthwick Kathleen

Mon, 12 Jan 2026 16:03:00 -0500

si-local-file:///var/storage/secattach/20260112/25837785.html

Form 8-K Passage BIO, Inc. For: Jan 12

Mon, 12 Jan 2026 07:02:00 -0500

si-local-file:///var/storage/secattach/20260112/25833955.html

Form 8-K Passage BIO, Inc. For: Jan 12

Mon, 12 Jan 2026 07:02:00 -0500

si-local-file:///var/storage/secattach/20260112/25833955.html

Form 144 Passage BIO, Inc. Filed by: Chou William

Fri, 09 Jan 2026 16:03:00 -0500

si-local-file:///var/storage/secattach/20260109/25831257.html

Form 144 Passage BIO, Inc. Filed by: Chou William

Fri, 09 Jan 2026 16:03:00 -0500

si-local-file:///var/storage/secattach/20260109/25831257.html